Welcome to our dedicated page for Nextcure news (Ticker: NXTC), a resource for investors and traders seeking the latest updates and insights on Nextcure stock.
NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biopharmaceutical company focused on developing targeted therapies, including antibody-drug conjugates, for cancer patients who do not respond to, or have disease progression on, current treatments. The NXTC news feed highlights company announcements that trace the progress of its pipeline and corporate strategy.
Investors and followers of NextCure can use this page to review updates on its lead ADC programs, SIM0505 and LNCB74. News items include business updates and quarterly financial results, where the company discusses clinical trial status, dose escalation progress and plans for proof-of-concept data readouts in advanced solid tumors. Press releases also cover preclinical findings for programs such as NC605 in osteogenesis imperfecta and NC181 in Alzheimer’s disease models.
NXTC news frequently addresses strategic partnerships and licensing agreements, such as the collaboration with Simcere Zaiming for SIM0505 and the co-development arrangement with LigaChem Biosciences Inc. for LNCB74. Readers will also find coverage of scientific presentations at major conferences, including trial-in-progress posters and preclinical data presentations.
In addition, the feed includes capital markets and corporate developments reported by NextCure, such as private placements of common stock and pre-funded warrants, reverse stock split implementation, and changes in executive leadership. These disclosures provide context on how the company finances its research and manages its listing on the Nasdaq Global Select Market.
By reviewing the NXTC news page regularly, users can follow the evolution of NextCure’s oncology-focused pipeline, its non-oncology preclinical efforts, and key corporate decisions that may influence the company’s development plans and financial position.
NextCure (Nasdaq: NXTC) presented clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab at ESMO 2024. The trial demonstrated clinical activity in hard-to-treat cancers, including ovarian cancer and immune checkpoint inhibitor (ICI) naïve microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC).
Key results include:
- 5 partial responses (PRs) out of 20 evaluable ovarian cancer patients
- 3 PRs out of 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis
- Biomarker data supporting the proposed mechanism of action of NC410
The combination showed durable responses in both tumor types, which are generally unresponsive to immunotherapy. NextCure plans to provide an update on patients remaining in the study later this year.
NextCure (Nasdaq: NXTC) provided a business update and reported Q2 2024 financial results. Key highlights include:
1. Completed enrollment of 16 additional ovarian cancer patients in the NC410 + pembrolizumab Phase 1b study.
2. Finished GLP toxicology studies for LNCB74 (B7-H4 ADC), targeting IND submission by year-end.
3. Cash position of $86.4 million, expected to fund operations into H2 2026.
4. Q2 2024 financials: R&D expenses $12.4M, G&A expenses $4.1M, net loss $15.4M.
5. On track to present expanded ovarian cancer cohort data and CRC update in Q4 2024.
6. Advancing NC181 (APOE4) and NC605 (Siglec-15) programs, seeking partnerships for IND filings.
NextCure, a clinical-stage biopharmaceutical company listed on Nasdaq as NXTC, has announced its participation in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference.
The event is scheduled for June 27, 2024. NextCure will present and host meetings with institutional investors.
A recording of the webcast will be accessible starting at 7 AM ET on the same day through the Investors section of NextCure’s website, www.nextcure.com, and will remain available for 30 days.
NextCure (Nasdaq: NXTC) announced promising results from its Phase 1b study of NC410 in combination with pembrolizumab, presented at ASCO 2024. The study focused on patients with MSS/MSI-L colorectal cancer (CRC) and ovarian cancer. Key findings include a 51% disease control rate in CRC patients and a 43% rate in ovarian cancer patients. Two CRC patients had ongoing partial responses (PR) and a median disease control duration of 5.5 months. In ovarian cancer, three patients experienced PRs with a 43% overall response rate. Adverse events were mostly mild, but 39.5% of patients had Grade ≥3 Treatment Emergent Adverse Events (TEAE), and 4.9% had Grade ≥3 Treatment-Related Adverse Events (TRAE). A poster presentation by Dr. Eric S. Christenson will detail these findings on June 1, 2024, at the ASCO Annual Meeting in Chicago.
NextCure, a clinical-stage biopharmaceutical company, reported its first-quarter 2024 financial results and provided a business update. They highlighted presenting Phase 1b data for NC410 combo with pembro at the ASCO Annual Meeting, showcasing preclinical data from LNCB74 at the AACR Annual Meeting, and having cash of approximately $96.0 million to fund operations into the second half of 2026. The company is focused on developing novel cancer therapies.
FAQ
What is the current stock price of Nextcure (NXTC)?
What is the market cap of Nextcure (NXTC)?
